- Home
- KRYS vs AXSM Comparison
KRYS vs AXSM Comparison
Compare KRYS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRYS | AXSM |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 12.0B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KRYS | AXSM |
|---|---|---|
| Price | $338.13 | $244.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $297.60 | $211.12 |
| AVG Volume (30 Days) | 294.7K | ★ 632.7K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | 38.56 |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $38.74 | $57.24 |
| Revenue Next Year | $32.53 | $55.88 |
| P/E Ratio | $187.67 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $130.50 | $96.09 |
| 52 Week High | $356.50 | $260.19 |
Technical Indicators
Market Signals| Indicator | KRYS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 59.02 |
| Support Level | $253.89 | $148.87 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 12.77 | 8.88 |
| MACD | 2.68 | -0.97 |
| Stochastic Oscillator | 72.67 | 63.58 |
Price Performance
Historical ComparisonAbout KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.